Literature DB >> 3084647

Induction of protective immunity against Schistosoma mansoni by a nonliving vaccine. IV. Fractionation and antigenic properties of a soluble adult worm immunoprophylactic activity.

A Sher, E Pearce, S Hieny, S James.   

Abstract

An aqueous buffer-soluble, nonparticulate fraction of adult Schistosoma mansoni worms (SWAP) was separated by gel filtration on Ultragel AcA-34, and portions of the eluate were tested for their capacity to induce protective immunity against cercarial challenge when administered intradermally to mice in combination with the adjuvant BCG. All of the immunogenic activity was found in a single peak of protein excluded in the void volume of the column. This same fraction was determined by SDS-PAGE and Western immunoblotting to be unique in that it contained a component of Mr (X 10(-3) 97 (97,000) recognized monospecifically by antibodies from mice vaccinated with unseparated SWAP plus BCG. Similarly, the protective fraction was unique in possessing the capacity to elicit 24 hr delayed footpad swelling responses, as well as lymphokine production, in SWAP-BCG-immunized mice. These results suggest that the immunogenic activity of SWAP resides in a restricted population of molecules, and possibly in the 97,000 antigen detected with antibodies from vaccinated animals. Because both the protective capacity of unfractionated SWAP and the serologic reactivity of the 97,000 antigen are sensitive to digestion with protease, it is likely that the immunologic activity of these molecules is dependent on peptide-bonded structural elements.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3084647

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Human immune responses to Schistosoma mansoni vaccine candidate antigens.

Authors:  A Ribeiro de Jesus; I Araújo; O Bacellar; A Magalhães; E Pearce; D Harn; M Strand; E M Carvalho
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

2.  T-helper-2 cytokine responses to Sj97 predict resistance to reinfection with Schistosoma japonicum.

Authors:  Tjalling Leenstra; Luz P Acosta; Hai-Wei Wu; Gretchen C Langdon; Julie S Solomon; Daria L Manalo; Li Su; Mario Jiz; Blanca Jarilla; Archie O Pablo; Stephen T McGarvey; Remigio M Olveda; Jennifer F Friedman; Jonathan D Kurtis
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  Induction of resistance to Schistosoma mansoni infection in mice by purified parasite paramyosin.

Authors:  T P Flanigan; C H King; R R Lett; J Nanduri; A A Mahmoud
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

4.  Effect of cholera toxin on vaccine-induced immunity and infection in murine schistosomiasis mansoni.

Authors:  A A Akhiani; L A Nilsson; O Ouchterlony
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

5.  Induction of protective immunity against Schistosoma mansoni by vaccination with schistosome paramyosin (Sm97), a nonsurface parasite antigen.

Authors:  E J Pearce; S L James; S Hieny; D E Lanar; A Sher
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

6.  Antiidiotypic antibody vaccine in murine Schistosomiasis mansoni comprising the internal image of antigen.

Authors:  T F Kresina; G R Olds
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

Review 7.  Development of Paramyosin as a Vaccine Candidate for Schistosomiasis.

Authors:  Mario A Jiz; Haiwei Wu; Remigio Olveda; Blanca Jarilla; Jonathan D Kurtis
Journal:  Front Immunol       Date:  2015-07-21       Impact factor: 7.561

Review 8.  Schistosome Vaccine Adjuvants in Preclinical and Clinical Research.

Authors:  Rachel Stephenson; Hong You; Donald P McManus; Istvan Toth
Journal:  Vaccines (Basel)       Date:  2014-09-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.